Evidence map›Paper›PMID 32458401›Full record

ArticleJournal of cardiovascular translational research2020

MicroRNA-208a: a Good Diagnostic Marker and a Predictor of no-Reflow in STEMI Patients Undergoing Primary Percutaneuos Coronary Intervention.

Aboubakr Mohamed Salama, Wael Ali Khalil, Manar Al-Zaky, Somia Hassan Abdallah, Nader Talaat Kandil, Ahmed Abdelsabour, Ahmed Mohammed Shaker, Mesbah Taha Hasanein, Giovanni Battista Luciani, Hassan M E Azzazy

Erratum issuedAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Aboubakr Mohamed SalamaCardiovascular Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt. abobakr@aucegypt.edu.ORCID http://orcid.org/0000-0002-2241-3792
Wael Ali KhalilCardiovascular Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Manar Al-ZakyCardiovascular Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Somia Hassan AbdallahMedical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Nader Talaat KandilCardiovascular Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Ahmed AbdelsabourClinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Ahmed Mohammed ShakerMedical Physiology Department, National Research Center, Cairo, Egypt.
Mesbah Taha HasaneinCardiovascular Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Giovanni Battista LucianiDepartment of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Verona, Italy.
Hassan M E AzzazyDepartment of Chemistry, School of Science and Engineering, The American University in Cairo, Cairo, Egypt.
Zagazig University · EGUniversity of Verona · ITAmerican University in Cairo · EGNational Water Research Center · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA-208a is a cardiac specific oligo-nucleotide. We aimed at investigating the ability of microRNA-208a to diagnose myocardial infarction and predict the outcome of primary percutaneuos coronary angiography (PCI). Patients (n = 75) presented by chest pain were recruited into two groups. Group 1 (n = 40) had ST elevation myocardial infarction (STEMI) and underwent primary PCI: 21 patients had sufficient reperfusion and 19 had no-reflow. Group 2 (n = 35) had negative cardiac troponins (cTns). Plasma microRNA-208a expression was assessed using quantitative polymerase chain reaction and patients were followed for occurrence of in-hospital major adverse cardiac events (MACE). MicroRNA-208a could diagnose of MI (AUC of 0.926). After primary PCI, it was superior to cTnT in prediction of no-reflow (AUC difference of 0.231, P = 0.0233) and MACE (AUC difference of 0.367, P = 0.0053). Accordingly, circulating levels of miR-208a can be used as a diagnostic marker of MI and a predictor of no-reflow and in-hospital MACE. Graphical abstract Receiver operating curve analysis of no-reflow prediction of miRNA208a, CK-MB and hs-Troponin T. MicroRNA-208a shows significantly higher prediction of no-reflow as compared to routine cardiac biomarkers.

Indexed as

AgedBiomarkersCoronary AngiographyFemaleHumansMaleMicroRNAsMiddle AgedNo-Reflow PhenomenonPercutaneous Coronary InterventionPredictive Value of TestsReal-Time Polymerase Chain ReactionST Elevation Myocardial InfarctionTreatment OutcomeTroponin TBiomarkersMicroRNAsMIRN208 microRNA, humanTroponin TMicroRNAMyocardial infarctionNo-reflowPrimary PCI

Identifiers

PMID32458401
OpenAlexW3031594156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.